# Hexcel Corp: financial statements, quarterly

HXL · NYSE · CIK 717605 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hxl.md) · [Financials](/companies/hxl/financials.md) · [Filings](/companies/hxl/filings.md) · [Insiders](/companies/hxl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hxl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [458 d](/filings/0001193125-26-046377.md) | [472](/filings/0000950170-25-056328.md) | [500](/filings/0000950170-25-098369.md) | [457](/filings/0001193125-25-246968.md) | [474 d](/filings/0001193125-26-046377.md) | [457](/filings/0001193125-26-170597.md) | [490](/filings/0001193125-26-323941.md) | [456](/filings/0001193125-26-427907.md) | [491 d](/filings/0001193125-26-046377.md) | [502](/filings/0001193125-26-170597.md) | [529](/filings/0001193125-26-323941.md) | [496](/filings/0001193125-26-427907.md) |
| Cost of revenue | $m | [354 d](/filings/0001193125-26-046377.md) | [354](/filings/0000950170-25-056328.md) | [374](/filings/0000950170-25-098369.md) | [350](/filings/0001193125-25-246968.md) | [355 d](/filings/0001193125-26-046377.md) | [354](/filings/0001193125-26-170597.md) | [378](/filings/0001193125-26-323941.md) | [356](/filings/0001193125-26-427907.md) | [370 d](/filings/0001193125-26-046377.md) | [367](/filings/0001193125-26-170597.md) | [391](/filings/0001193125-26-323941.md) | [381](/filings/0001193125-26-427907.md) |
| Gross profit | $m | [103 d](/filings/0001193125-26-046377.md) | [118](/filings/0000950170-25-056328.md) | [127](/filings/0000950170-25-098369.md) | [107](/filings/0001193125-25-246968.md) | [119 d](/filings/0001193125-26-046377.md) | [102](/filings/0001193125-26-170597.md) | [112](/filings/0001193125-26-323941.md) | [99.9](/filings/0001193125-26-427907.md) | [121 d](/filings/0001193125-26-046377.md) | [135](/filings/0001193125-26-170597.md) | [138](/filings/0001193125-26-323941.md) | [116](/filings/0001193125-26-427907.md) |
| Research and development | $m | [12.1 d](/filings/0001193125-26-046377.md) | [15.1](/filings/0000950170-25-056328.md) | [14.7](/filings/0000950170-25-098369.md) | [13.8](/filings/0001193125-25-246968.md) | [13.5 d](/filings/0001193125-26-046377.md) | [13.8](/filings/0001193125-26-170597.md) | [14.3](/filings/0001193125-26-323941.md) | [14.0](/filings/0001193125-26-427907.md) | [14.3 d](/filings/0001193125-26-046377.md) | [17.8](/filings/0001193125-26-170597.md) | [17.3](/filings/0001193125-26-323941.md) | [16.2](/filings/0001193125-26-427907.md) |
| Selling, general and administrative | $m | [41.9 d](/filings/0001193125-26-046377.md) | [49.0](/filings/0000950170-25-056328.md) | [39.9](/filings/0000950170-25-098369.md) | [39.8](/filings/0001193125-25-246968.md) | [47.9 d](/filings/0001193125-26-046377.md) | [43.3](/filings/0001193125-26-170597.md) | [43.0](/filings/0001193125-26-323941.md) | [41.1](/filings/0001193125-26-427907.md) | [41.6 d](/filings/0001193125-26-046377.md) | [49.4](/filings/0001193125-26-170597.md) | [47.2](/filings/0001193125-26-323941.md) | [44.9](/filings/0001193125-26-427907.md) |
| Operating income | $m | [47.6 d](/filings/0001193125-26-046377.md) | [52.9](/filings/0000950170-25-056328.md) | [71.8](/filings/0000950170-25-098369.md) | [52.5](/filings/0001193125-25-246968.md) | [8.9 d](/filings/0001193125-26-046377.md) | [44.2](/filings/0001193125-26-170597.md) | [30.0](/filings/0001193125-26-323941.md) | [36.0](/filings/0001193125-26-427907.md) | [61.4 d](/filings/0001193125-26-046377.md) | [57.6](/filings/0001193125-26-170597.md) | [72.6](/filings/0001193125-26-323941.md) | [54.8](/filings/0001193125-26-427907.md) |
| Interest expense | $m | [7.6 d](/filings/0001193125-26-046377.md) | [6.5](/filings/0000950170-25-056328.md) | [8.1](/filings/0000950170-25-098369.md) | [8.5](/filings/0001193125-25-246968.md) | [8.1 d](/filings/0001193125-26-046377.md) | [7.8](/filings/0001193125-26-170597.md) | [9.1](/filings/0001193125-26-323941.md) | [9.2](/filings/0001193125-26-427907.md) | [11.6 d](/filings/0001193125-26-046377.md) | [11.8](/filings/0001193125-26-170597.md) | [12.0](/filings/0001193125-26-323941.md) | [12.1](/filings/0001193125-26-427907.md) |
| Income tax | $m | [(10.4) d](/filings/0001193125-26-046377.md) | [9.9](/filings/0000950170-25-056328.md) | [13.7](/filings/0000950170-25-098369.md) | [4.2](/filings/0001193125-25-246968.md) | [(5.0) d](/filings/0001193125-26-046377.md) | [7.1](/filings/0001193125-26-170597.md) | [8.3](/filings/0001193125-26-323941.md) | [6.2](/filings/0001193125-26-427907.md) | [4.0 d](/filings/0001193125-26-046377.md) | [8.3](/filings/0001193125-26-170597.md) | [11.4](/filings/0001193125-26-323941.md) | [4.1](/filings/0001193125-26-427907.md) |
| Net income | $m | [(18.2) d](/filings/0001193125-26-046377.md) | [36.5](/filings/0001193125-25-246968.md) | [50.0](/filings/0001193125-25-246968.md) | [39.8](/filings/0001193125-25-246968.md) | [5.8 d](/filings/0001193125-26-046377.md) | [28.9](/filings/0001193125-26-427907.md) | [13.5](/filings/0001193125-26-427907.md) | [20.6](/filings/0001193125-26-427907.md) | [46.4 d](/filings/0001193125-26-046377.md) | [37.2](/filings/0001193125-26-427907.md) | [49.3](/filings/0001193125-26-427907.md) | [38.6](/filings/0001193125-26-427907.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: not reported

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [227](/filings/0000950170-25-014412.md) | [85.9](/filings/0000950170-24-046457.md) | [75.4](/filings/0000950170-24-084437.md) | [98.2](/filings/0000950170-24-115969.md) | [125](/filings/0001193125-26-046377.md) | [89.2](/filings/0000950170-25-056328.md) | [77.2](/filings/0000950170-25-098369.md) | [90.5](/filings/0001193125-25-246968.md) | [71.0](/filings/0001193125-26-427907.md) | [54.1](/filings/0001193125-26-170597.md) | [62.2](/filings/0001193125-26-323941.md) | [77.8](/filings/0001193125-26-427907.md) |
| Current assets | $m | [864](/filings/0000950170-25-014412.md) | [790](/filings/0000950170-24-046457.md) | [808](/filings/0000950170-24-084437.md) | [828](/filings/0000950170-24-115969.md) | [782](/filings/0001193125-26-046377.md) | [823](/filings/0000950170-25-056328.md) | [847](/filings/0000950170-25-098369.md) | [787](/filings/0001193125-25-246968.md) | [731](/filings/0001193125-26-427907.md) | [770](/filings/0001193125-26-170597.md) | [792](/filings/0001193125-26-323941.md) | [798](/filings/0001193125-26-427907.md) |
| Total assets | $m | [2,919](/filings/0001193125-26-046377.md) | [2,821](/filings/0000950170-24-046457.md) | [2,828](/filings/0000950170-24-084437.md) | [2,862](/filings/0000950170-24-115969.md) | [2,726](/filings/0001193125-26-046377.md) | [2,779](/filings/0000950170-25-056328.md) | [2,843](/filings/0000950170-25-098369.md) | [2,758](/filings/0001193125-25-246968.md) | [2,704](/filings/0001193125-26-427907.md) | [2,724](/filings/0001193125-26-170597.md) | [2,731](/filings/0001193125-26-323941.md) | [2,729](/filings/0001193125-26-427907.md) |
| Current liabilities | $m | [316](/filings/0000950170-25-014412.md) | [289](/filings/0000950170-24-046457.md) | [294](/filings/0000950170-24-084437.md) | [300](/filings/0000950170-24-115969.md) | [354](/filings/0001193125-26-046377.md) | [318](/filings/0000950170-25-056328.md) | [316](/filings/0000950170-25-098369.md) | [286](/filings/0001193125-25-246968.md) | [323](/filings/0001193125-26-427907.md) | [314](/filings/0001193125-26-170597.md) | [326](/filings/0001193125-26-323941.md) | [311](/filings/0001193125-26-427907.md) |
| Total liabilities | $m | [1,202](/filings/0000950170-25-014412.md) | [1,189](/filings/0000950170-24-046457.md) | [1,256](/filings/0000950170-24-084437.md) | [1,273](/filings/0000950170-24-115969.md) | [1,198](/filings/0001193125-26-046377.md) | [1,247](/filings/0000950170-25-056328.md) | [1,289](/filings/0000950170-25-098369.md) | [1,192](/filings/0001193125-25-246968.md) | [1,453](/filings/0001193125-26-427907.md) | [1,458](/filings/0001193125-26-170597.md) | [1,432](/filings/0001193125-26-323941.md) | [1,405](/filings/0001193125-26-427907.md) |
| Long-term debt | $m | [699](/filings/0000950170-25-014412.md) | [715](/filings/0000950170-24-046457.md) | [795](/filings/0000950170-24-084437.md) | [805](/filings/0000950170-24-115969.md) | [701](/filings/0001193125-26-046377.md) | [787](/filings/0000950170-25-056328.md) | [828](/filings/0000950170-25-098369.md) | [758](/filings/0001193125-25-246968.md) | [993](/filings/0001193125-26-427907.md) | [998](/filings/0001193125-26-170597.md) | [959](/filings/0001193125-26-323941.md) | [935](/filings/0001193125-26-427907.md) |
| Current portion of debt | $m | [0.1](/filings/0000950170-25-014412.md) | [0.1](/filings/0000950170-24-046457.md) | [0.1](/filings/0000950170-24-084437.md) | [0.1](/filings/0000950170-24-115969.md) | [0.1](/filings/0001193125-26-046377.md) | [0.1](/filings/0000950170-25-056328.md) | [0.0](/filings/0000950170-25-098369.md) | [0.0](/filings/0001193125-25-246968.md) | [0.0](/filings/0001193125-26-046377.md) | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [1,717](/filings/0001193125-26-046377.md) | [1,632](/filings/0001193125-25-246968.md) | [1,571](/filings/0001193125-25-246968.md) | [1,590](/filings/0001193125-25-246968.md) | [1,528](/filings/0001193125-26-427907.md) | [1,533](/filings/0001193125-26-427907.md) | [1,554](/filings/0001193125-26-427907.md) | [1,567](/filings/0001193125-26-427907.md) | [1,251](/filings/0001193125-26-427907.md) | [1,266](/filings/0001193125-26-427907.md) | [1,298](/filings/0001193125-26-427907.md) | [1,324](/filings/0001193125-26-427907.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [159 d](/filings/0001193125-26-046377.md) | [(7.0)](/filings/0000950170-25-056328.md) | [44.2 d](/filings/0000950170-25-098369.md) | [90.1 d](/filings/0001193125-25-246968.md) | [163 d](/filings/0001193125-26-046377.md) | [(28.5)](/filings/0001193125-26-170597.md) | [23.3 d](/filings/0001193125-26-323941.md) | [110 d](/filings/0001193125-26-427907.md) | [126 d](/filings/0001193125-26-046377.md) | [19.0](/filings/0001193125-26-170597.md) | [77.7 d](/filings/0001193125-26-323941.md) | [74.4 d](/filings/0001193125-26-427907.md) |
| Capital expenditure | $m | [13.8 d](/filings/0001193125-26-046377.md) | [28.7](/filings/0000950170-25-056328.md) | [22.9 d](/filings/0000950170-25-098369.md) | [16.8 d](/filings/0001193125-25-246968.md) | [18.6 d](/filings/0001193125-26-046377.md) | [26.1](/filings/0001193125-26-170597.md) | [15.3 d](/filings/0001193125-26-323941.md) | [13.7 d](/filings/0001193125-26-427907.md) | [18.2 d](/filings/0001193125-26-046377.md) | [25.2](/filings/0001193125-26-170597.md) | [19.7 d](/filings/0001193125-26-323941.md) | [23.7 d](/filings/0001193125-26-427907.md) |
| Dividends paid | $m | [10.5 d](/filings/0001193125-26-046377.md) | [12.6](/filings/0000950170-25-056328.md) | [12.4 d](/filings/0000950170-25-098369.md) | [12.2 d](/filings/0001193125-25-246968.md) | [12.1 d](/filings/0001193125-26-046377.md) | [13.8](/filings/0001193125-26-170597.md) | [13.7 d](/filings/0001193125-26-323941.md) | [13.5 d](/filings/0001193125-26-427907.md) | [12.9 d](/filings/0001193125-26-046377.md) | [13.7](/filings/0001193125-26-170597.md) | [13.6 d](/filings/0001193125-26-323941.md) | [13.6 d](/filings/0001193125-26-427907.md) |
| Share repurchases | $m | [0.0 d](/filings/0001193125-26-046377.md) | [101](/filings/0000950170-25-056328.md) | [101 d](/filings/0000950170-25-098369.md) | [50.4 d](/filings/0001193125-25-246968.md) | [0.0 d](/filings/0001193125-26-046377.md) | [50.4](/filings/0001193125-26-170597.md) | [50.5 d](/filings/0001193125-26-323941.md) | [0.0 d](/filings/0001193125-26-427907.md) | [353 d](/filings/0001193125-26-046377.md) | [0.0](/filings/0001193125-26-170597.md) | [0.0 d](/filings/0001193125-26-323941.md) | [0.0 d](/filings/0001193125-26-427907.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [85.5](/filings/0000950170-24-046457.md) | [85.6](/filings/0000950170-24-084437.md) | [85.6](/filings/0000950170-24-115969.md) | [84.8](/filings/0000950170-25-056328.md) | [83.2](/filings/0000950170-25-098369.md) | [82.1](/filings/0001193125-25-246968.md) | [81.7](/filings/0001193125-26-170597.md) | [80.6](/filings/0001193125-26-323941.md) | [80.3](/filings/0001193125-26-427907.md) | [76.7](/filings/0001193125-26-170597.md) | [76.5](/filings/0001193125-26-323941.md) | [76.7](/filings/0001193125-26-427907.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 75,701,918 at 2026-10-19, from the cover of the [10-Q filed 2026-10-21](/filings/0001193125-26-427907.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.